Ab&B Bio Tech Co Ltd JS

Ab&B Bio Tech Co Ltd JS EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Ab&B Bio Tech Co Ltd JS (2627.HK) as of Oct 15, 2026 is -75.05. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -47.68 — a change of 57.39% (lower).

EV/OCF

-75.05

YoY

57.39%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Ab&B Bio Tech Co Ltd JS is 2024 -75.05 . EV/OCF (Enterprise Value to Operating Cash Flow) of Ab&B Bio Tech Co Ltd JS was 2023 -47.68 . It decreases by 57.39% lower compared to the previous year.

The Ab&B Bio Tech Co Ltd JS EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2023
-47.68 CNY
Jan 1, 2024
-75.05 CNY
The Ab&B Bio Tech Co Ltd JS EV/OCF history
YEAREV/OCFYoY
-75.05+57.39%
-47.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ab&B Bio Tech Co Ltd JS Stock analysis

What does Ab&B Bio Tech Co Ltd JS do? Ab&B Bio Tech Co Ltd JS is a biotechnology company headquartered in Taizhou, China, operating within the healthcare sector. The company is engaged in the research, development, manufacturing, and commercialization of vaccines. It has a product pipeline featuring two core vaccine candidates: a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine. Additionally, the company has 11 other vaccine candidates in its pipeline. Ab&B Bio Tech Co Ltd JS is listed on the Hong Kong Stock Exchange with ticker 2627.HK and ISIN CNE1000071P9. The company's initial public offering (IPO) is scheduled for August 8, 2025. Its website is http://www.abbbio.com/. The company primarily serves the domestic market in China. Ab&B Bio Tech Co Ltd JS is a China-based entity with operations focused on biotechnology within the healthcare industry. The company's activities are centered around vaccine development and commercialization, targeting both existing and emerging market needs within China. Ab&B Bio Tech Co Ltd JS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ab&B Bio Tech Co Ltd JS stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Ab&B Bio Tech Co Ltd JS is -75.05 in 2024.

EV/OCF (Enterprise Value to Operating Cash Flow) of Ab&B Bio Tech Co Ltd JS changed from -47.68 to -75.05, representing a 57.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Ab&B Bio Tech Co Ltd JS since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Ab&B Bio Tech Co Ltd JS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Ab&B Bio Tech Co Ltd JS

All Key Metrics — Ab&B Bio Tech Co Ltd JS